CONFIDENTIAL TREATMENT [***] DENOTES OMISSIONS Memorandum Of UnderstandingsConfidential Treatment • June 5th, 2018 • Wize Pharma, Inc. • Pharmaceutical preparations
This memorandum of understanding (this "MOU") is entered this January 8, 2018 and is intended to reflect our mutual agreement concerning the contemplated assignment of distribution rights and a license from Resdevco Research and Development Ltd. (Private Company 510422223, hereinafter "Resdevco") to Wize Pharma Ltd. of Hanagr 5b Hod Hasharon, Israel (“Wize”).
